PB1829: ARGENTINEAN REAL WORLD EXPERIENCE ON MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY VS INTENSIVE CHEMOTHERAPY TO TREAT FLT3 POSITIVE ACUTE MYELOID LEUKEMIA PATIENTS

Bibliographic Details
Published in:	HemaSphere
Main Authors:	A. Navickas, J. González, M. M. Rivas, M. Clavijo, N. Carnelutto, M. E. Funes, M. J. Mela Osorio, R. Mariano, M. L. Rapan, M. Moirano, I. Rey, S. Cranco, J. E. Giunta, R. Ramirez, M. B. Castro, A. Enrico, A. Gimenez Conca, C. Belli
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000850168.39267.76

Similar Items

P523: MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY IN FLT3 MUTATED AML. “REAL LIFE” DATA VERSUS THE RATIFY STUDY
by: A. De La Fuente, et al.
Published: (2022-06-01)

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
by: Frank G. Rücker, et al.
Published: (2024-12-01)

S126: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. RESULTS FROM THE NCRI AML19 “MIDOTARG” PILOT TRIAL
by: N. Russell, et al.
Published: (2022-06-01)

S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN
by: Frank G Rücker, et al.
Published: (2023-08-01)

Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemiaResearch in context
by: Weronika E. Borek, et al.
Published: (2024-10-01)

Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and <i>KIT</i> and/or <i>FLT3</i>- ITD mutations: results of the SAL MIDOKIT trial
by: Leo Ruhnke, et al.
Published: (2023-02-01)

P536: VALUE OF MEASURABLE RESIDUAL DISEASE BY MULTIPARAMETRIC FLOW CYTOMETRY IN NON-PROMYELOCYTIC ACUTE MYELOID LEUKEMIA. REAL WORLD EVIDENCE
by: A. D. Gimenez Conca, et al.
Published: (2022-06-01)

S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA
by: Arran Dokal, et al.
Published: (2023-08-01)

Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia
by: Romane Joudinaud, et al.
Published: (2025-01-01)

Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for <i>FLT3</i>- mutated acute myeloid leukemia patients – Czech center experience
by: Barbora Weinbergerová, et al.
Published: (2023-02-01)

MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
by: Katja Seipel, et al.
Published: (2018-11-01)

Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function
by: Denise Wolleschak, et al.
Published: (2014-06-01)

PB1890: TRIAL IN PROGRESS: A PHASE II STUDY OF MIDOSTAURIN COMBINED WITH INDUCTION/CONSOLIDATION CHEMOTHERAPY AND AS SINGLE-AGENT MAINTENANCE IN PEDIATRIC PATENTS WITH FLT3-MUTATED ACUTE MYELOID LEUKEMIA
by: Dirk Reinhardt, et al.
Published: (2023-08-01)

Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in <i>FLT3</I>-mutated acute myeloid leukemia
by: Julia S. Lee, et al.
Published: (2023-06-01)

P484: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL
by: Nigel Russell, et al.
Published: (2023-08-01)

Rhabdomyolysis in Patients with Hemoblastoses during Intensive Chemotherapy
by: A. V Lyanguzov, et al.
Published: (2009-08-01)

Regional disparities in the use of intensive chemotherapy for AML in the Netherlands: does it influence survival?
by: Hester F Lingsma, et al.
Published: (2024-07-01)

P764: RESPONSE AND SURVIVAL OUTCOMES WITH HYPOMETHYLATING AGENTS IN AN ARGENTINEAN COHORT OF 113 PATIENTS WITH CHRONIC MYELOMONOCITIC LEUKEMIA
by: J. Gonzalez, et al.
Published: (2022-06-01)

Feasibility of Intensive Chemotherapy in Hereditary Spherocytosis
by: Carrai Valentina, et al.
Published: (2025-02-01)

Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy
by: Seth E. Karol, et al.
Published: (2021-07-01)

P514: V-FAST MASTER TRIAL: PRELIMINARY RESULTS OF TREATMENT WITH CPX-351 PLUS MIDOSTAURIN IN ADULTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA
by: J. McCloskey, et al.
Published: (2022-06-01)

The importance of intensive chemotherapy for advanced Hodgkin lymphoma in children
by: E.S. Belyaeva, et al.
Published: (2020-06-01)

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
by: Mar Tormo, et al.
Published: (2023-08-01)

PB2122: THE EFFICACY OF THE STANDARD AND INTENSIVE CHEMOTHERAPY IN ELDERLY PATIENTS WITH DOUBLE- AND TRIPLE-EXPRESSOR LYMPHOMA.
by: M. Fujita, et al.
Published: (2022-06-01)

Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma
by: Andreas Engert, et al.
Published: (2017-12-01)

Intensity-Modulated and Image-Guided Radiotherapy in Patients with Locally Advanced Inoperable Pancreatic Cancer after Preradiation Chemotherapy
by: M. Sinn, et al.
Published: (2014-01-01)

PB1809: CLINICAL TRAJECTORY OF LONG-TERM SURVIVORS OF ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE INDUCTION CHEMOTHERAPY
by: G. Heering, et al.
Published: (2022-06-01)

Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia
by: Marlise R. Luskin, et al.
Published: (2025-02-01)

Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy
by: Wei-Ying Jen, et al.
Published: (2025-02-01)

Multiplexed single‐cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells
by: Emma Rörby, et al.
Published: (2021-02-01)

Recurrent Hyperbilirubinemia with Midostaurin during Consolidation in a Patient of AML with FLT3 Mutation and Review of Literature for Alternative Maintenance Strategy
by: Deepak Kumar Shukla, et al.
Published: (2025-08-01)

Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3
by: Hao Lu, et al.
Published: (2022-07-01)

P547: UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING
by: Jacopo Nanni, et al.
Published: (2023-08-01)

P064 | TARGETING AUTOPHAGY ENHANCES MIDOSTAURIN'S EFFICACY AGAINST FLT3-MUTATED ACUTE MYELOID LEUKEMIA UNDER CONDITIONS MIMICKING THE HYPOXIC BONE MERROW MICROENVIRONMENT
by: C. Mosca, et al.
Published: (2025-09-01)

THERAPEUTIC OPTIONS FOR PATIENTS WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY
by: Elihu Estey
Published: (2013-07-01)

HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era
by: J. A. Rodrigo, et al.
Published: (2012-01-01)

Bending strength and stiffness of poles of argentinean Eucalyptus grandis
by: Torrán E.A, et al.
Published: (2014-12-01)

Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study
by: Pierantonio Menna, et al.
Published: (2023-10-01)

P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT
by: Anjali Cremer, et al.
Published: (2023-08-01)

Potential Effects of the FLT3-ITD Mutation on Chemotherapy Response and Prognosis of Acute Promyelocytic Leukemia
by: Song Y, et al.
Published: (2021-03-01)